Patents Assigned to Thromgen, Inc.
  • Synthetic peptide analogs of Arg-Pro-Pro-Gly-Phe as selective inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4
    Patent number: 7074765
    Abstract: The invention relates to compounds and methods for inhibiting human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4 using peptide analogs of Arg-Pro-Pro-Gly-Phe that contain one or more amino acid substitutions. The invention also includes screening methods for identifying compounds that inhibit thrombin mediated activities.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: July 11, 2006
    Assignees: The Regents of the University of Michigan, Thromgen, Inc.
    Inventors: Alvin H. Schmaier, Ahmed A. K. Hasan
  • Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1
    Patent number: 6544750
    Abstract: The invention relates to inhibiting human platelet aggregation, thrombosis and cell activation mediated by PAR1 with peptide analogs corresponding to those of Formula I and II, wherein Formula I is: Arg-Gly-Lys-Z4-Cys wherein: Z4 is any naturally occurring amino acid, excluding cysteine; and wherein Formula II is: Arg-Gly-Asp-Z4-Cys wherein: Z4 is any naturally occurring amino acid, excluding cysteine.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: April 8, 2003
    Assignees: Thromgen, Inc., Regents of the University of Michigan
    Inventors: Alvin H. Schmaier, Ahmed A. K. Hasan